Department of Science and Technology Studies, Faulty of Science, University of Malaya, Kuala Lumpur, Malaysia.
Genovasi University College (GUC), Lot 2A (Gate C) Jalan 13/2, Seksyen 13, 46200, Petaling Jaya, Selangor, Malaysia.
Sci Eng Ethics. 2020 Feb;26(1):1-25. doi: 10.1007/s11948-019-00111-5. Epub 2019 May 23.
Stem cell technology is an emerging science field; it is the unique regenerative ability of the pluripotent stem cell which scientists hope would be effective in treating various medical conditions. While it has gained significant advances in research, it is a sensitive subject involving human embryo destruction and human experimentation, which compel governments worldwide to ensure that the related procedures and experiments are conducted ethically. Based on face-to-face interviews with selected Malaysian ethicists, scientists and policymakers, the objectives and effectiveness of the current Guideline for Stem Cell Research and Therapy (2009) are examined. The study's findings show that the guideline is rather ineffective in ensuring good ethical governance of the technology. A greater extent of unethical conduct is likely present in the private medical clinics or laboratories offering stem cell therapies compared with the public medical institutions providing similar services, as the latter are closely monitored by the governmental agencies enforcing the relevant policies and laws. To address concerns over malpractices or unethical conduct, this paper recommends a comprehensive revision of the current stem cell guideline so that adequate provisions exist to regulate the explicit practices of the private and public stem cell sectors, including false advertising and accountability. The newly revised Malaysian stem cell guideline will align with the Guidelines for Stem Cell Research and Clinical Translation (2016) of the International Society for Stem Cell Research (ISSCR) containing secular but universal moral rules. However, a regulatory policy formulated to govern the technology remains the main thrust of empowering the guideline for compliance among the stakeholders.
干细胞技术是一个新兴的科学领域;正是由于多能干细胞的独特再生能力,科学家们希望它能有效地治疗各种医学病症。虽然在研究方面已经取得了重大进展,但它是一个涉及人类胚胎破坏和人体实验的敏感话题,这迫使世界各国政府确保相关程序和实验符合伦理道德。本研究通过对选定的马来西亚伦理学家、科学家和政策制定者进行面对面访谈,考察了现行《干细胞研究与治疗指南》(2009 年)的目标和有效性。研究结果表明,该指南在确保对该技术进行良好的伦理治理方面效果不佳。与提供类似服务的公立医疗机构相比,提供干细胞治疗的私立医疗诊所或实验室中更有可能存在不道德行为,因为后者受到执行相关政策和法律的政府机构的密切监督。为了解决对不当行为或不道德行为的担忧,本文建议全面修订现行的干细胞指南,以便对包括虚假广告和问责制在内的私营和公共干细胞部门的明确做法进行监管。新修订的马来西亚干细胞指南将符合国际干细胞研究学会(ISSCR)的《干细胞研究和临床转化指南》(2016 年),其中包含非宗教但普遍适用的道德规则。然而,制定一项监管政策来管理该技术仍然是赋予该指南在利益相关者中合规的主要动力。